| Similar Articles |
|---|
 |
The Motley Fool
May 17, 2011
Brian Orelli |
$3 Million Here, $1.5 Billion There Isis makes progress in its pact with GlaxoSmithKline.   |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
March 4, 2011
Brian Orelli |
Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors. |
The Motley Fool
May 25, 2005
Brian Gorman |
Another Deal for Isis Investors shouldn't get their hopes up over the drugmaker's latest collaboration. |
The Motley Fool
February 17, 2004
David Nierengarten |
Antisense Making Sense? An update on Genasense, its future, and how the antisense marketplace is shaping up. The FDA has agreed to review the new drug applications. |
The Motley Fool
December 14, 2007
Brian Orelli |
An Overnight Three-Bagger It's not often you see stocks triple in one day, but that's what Rigel Pharmaceuticals did. You might be surprised, however, as to why. Investors, take note. |
The Motley Fool
November 8, 2010
Brian Orelli |
No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective. |
The Motley Fool
March 31, 2010
Brian Orelli |
A Double-Digit Jump? For That? Isis' drug discovery license doesn't look too exciting to me. |
The Motley Fool
April 16, 2010
Brian Orelli |
It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
January 9, 2008
Brian Orelli |
Genzyme Buys Into Antisense RNA -- Big Time Genzyme buys a piece of Isis' mipomersen at a wowser of a price. |
The Motley Fool
August 5, 2010
Brian Orelli |
Blockbuster Efficacy! Not-So-Blockbuster Safety! Isis and Genzyme's wonder drug has not-so-wonderful side effects. Still. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
The Motley Fool
November 18, 2009
Brian Orelli |
Drug Lowers Cholesterol; Stock Follows ISIS has a hard time at American Heart Association despite good efficacy data. |
The Motley Fool
May 15, 2007
Mike Havrilla |
Eyeing ISIS A robust pipeline and a promising cholesterol drug could benefit this pharmaceutical firm. Investors, take note. |
The Motley Fool
September 14, 2007
Brian Orelli |
J&J's Expensive RNA Purchase Johnson & Johnson sets up a collaboration with Isis Pharmaceuticals to develop compounds to treat diabetes. Investors take note. |
The Motley Fool
February 26, 2010
Brian Orelli |
A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus. |
The Motley Fool
February 11, 2010
Brian Orelli |
A Wonder Drug With Not-So-Wonderful Side Effects Wonder drug or not, Isis Pharmaceuticals and Genzyme's cholesterol drug mipomersen's sales will be limited by side effects. |
The Motley Fool
December 11, 2009
Brian Orelli |
Roche and Biogen's Blockbuster Making Good Progress Roche and Biogen move their potential blockbuster through the clinical trial maze. |
The Motley Fool
September 28, 2010
Brian Orelli |
Don't Get Stuck! Invest in Needle-Free Drugs Here's how to make some money off society's general disdain for needles through next-generation drugs. |
The Motley Fool
January 5, 2011
Brian Orelli |
Pfizer Goes Back for Seconds Headed back for more from Santaris. The company is putting up just $14 million for expanded access to Santaris' LNA technology. |
The Motley Fool
June 26, 2009
Brian Orelli |
The $16 Billion Market That Could Make You Rich A large market just waiting to be taken over. |
The Motley Fool
June 23, 2010
Brian Orelli |
A Novel Drug Technology Worth Watching Regulus signs up another microRNA partner. |
The Motley Fool
September 24, 2010
Brian Orelli |
Prepare for This $12 Billion Whoosh Pfizer's Lipitor is the top-selling cholesterol drug -- in fact, it's the top selling drug period -- but it'll start to see generic competition in a little over a year. |
The Motley Fool
January 11, 2011
Brian Orelli |
A Clear Drug-Development Path -- Times 2 The FDA throws a fork in the road for Isis and Genzyme. |
The Motley Fool
April 28, 2008
Brian Orelli |
FDA Moves Isis' Finish Line The FDA tells drugmaker Isis it must complete cancer tests before submitting its marketing application. |
The Motley Fool
February 10, 2004
David Nierengarten |
The Psoriasis Wars The pharma heavies are battling for the chronic skin disease's market. |
The Motley Fool
January 26, 2010
Brian Orelli |
Timing Is Everything for Amgen Amgen is counting on osteoporosis drug Prolia for a successful 2010. |
The Motley Fool
July 30, 2010
Brian Orelli |
On the Path to a Blockbuster Amgen's Prolia will be a blockbuster. Eventually. |
The Motley Fool
April 24, 2007
Ryan Fuhrmann |
Red and White Results at Amgen At current levels, this biotech titan could be worth a further look from investors. |
The Motley Fool
April 24, 2009
Brian Orelli |
The Economy Strikes Again Amgen isn't recession-proof either. |
The Motley Fool
June 22, 2010
Luke Timmerman |
Regulus Therapeutics Forms $750M MicroRNA Deal With Sanofi The company has found its second big ally from Big Pharma. |
The Motley Fool
February 4, 2008
Brian Lawler |
Genzyme Tells It Like It Is Genzyme shows some sparkle at investors' conference. Investors, take note. |
The Motley Fool
December 31, 2009
Brian Orelli |
Make Money Even When Drugs Fail Biotech growth potential without as much risk can come from innovations that help drugmakers discover new drugs. |
The Motley Fool
April 9, 2008
Brian Orelli |
Isis Ignited by Bristol-Myers Bristol-Myers Squibb selects an Isis-developed compound, triggering a milestone payment. |
The Motley Fool
October 4, 2007
Billy Fisher |
Isis Keeps Cholesterol Down, Stock Prices Up Isis Pharmaceuticals reports positive phase 2 results for a cholesterol treatment. The company continues to show progress with its impressive pipeline of 17 other development-stage drugs. Investors, take note. |
The Motley Fool
February 23, 2005
Brian Gorman |
Amgen Gets Disciplined Direct-to-consumer advertising may be a non-starter for Amgen and other biotech companies. |
The Motley Fool
November 22, 2011
Luke Timmerman |
Pfizer Acquires Excaliard, an Isis Spinout With Drug to Fight Excessive Scarring Pfizer is making a new bet on a new drug to fight excessive scarring. |
The Motley Fool
September 19, 2008
Brian Orelli |
Skinning the Competition J&J's psoriasis drug candidate beats Amgen and Wyeth's Enbrel. |
The Motley Fool
September 20, 2007
Brian Orelli |
A Pharma Divorce, and Good Riddance Merck and Alnylam call it quits. The only real question is why the two didn't end the partnership months ago. What will it mean to investors? |
The Motley Fool
May 20, 2009
Brian Orelli |
Clinical Trial Positive, Stock Not So Much Isis and Genzyme hit a homer with their cholesterol drug, mipomersen, but they'll need another big play to win the game. |
The Motley Fool
November 8, 2011
Anders Bylund |
Isis Pharmaceuticals' Shares Plunged: What You Need to Know Shares of drug developer Isis Pharmaceuticals hardly looked like a model of fertility today as they fell 10.5% in heavy intraday trading. |
The Motley Fool
February 9, 2006
Jason Mac Gurn |
RNA: Rule Breaker Nucleic Acid Investors, new RNA-based technologies may be the next revolution in biopharmaceuticals. ISIS Pharmaceuticals... Sirna Therapeutics... Alnylam Pharmaceuticals... |
The Motley Fool
December 17, 2008
Brian Orelli |
A Super-Cheap Call Option GlaxoSmithKline announces it's partnering up with tiny Dynavax Technologies to develop up to four drugs for autoimmune and inflammatory diseases. The pay-if-the-drug-works scheme should pay off. |
The Motley Fool
November 15, 2007
Brian Orelli |
Slowing the Cash Burn Bloody Nose Nastech plans to cut costs following Proctor& Gamble's drop of their osteoporosis drug. Investors, take note. |
The Motley Fool
July 20, 2011
Brian Orelli |
First in Class Isn't the Sweetest Position Bristol and AstraZeneca's diabetes drug dapagliflozin runs into trouble. |
The Motley Fool
May 22, 2008
Brian Orelli |
Merck Can't Achieve Anything The pharmaceutical cancels a troubled clinical trial. |
BusinessWeek
November 27, 2006
Gene G. Marcial |
ISIS Takes Heart From A Promising Drug ISIS Pharmaceuticals is a name to watch in the lucrative arena of cholesterol reduction. |
The Motley Fool
September 10, 2007
Brian Orelli |
Double Your RNA Pleasure Alnylam and ISIS join together to work on microRNAs. Their joint venture, called Regulus Therapeutics, combines their intellectual property in an effort to advance this new technology. Investors should take note. |
The Motley Fool
December 18, 2008
Brian Orelli |
A Diagnostic Tongue Twister Back-scratch fever between Abbott and Isis. |
